Increased production of asymmetric dimethylarginine (ADMA) in ankylosing spondylitis: Association with other clinical and laboratory parameters

Ádám Kemény-Beke, Rudolf Gesztelyi, Nóra Bodnár, Judit Zsuga, György Kerekes, Miklós Zsuga, Bernadett Biri, Sándor Kéki, Péter Szodoray, András Berta, Zoltán Szekanecz, Sándor Szántó

Research output: Article

19 Citations (Scopus)


Objective: Asymmetric dimethylarginine (ADMA) has been associated with atherosclerosis, vascular diseases and, recently, also with arthritis including rheumatoid arthritis (RA) and ankylosing spondylitis (AS). Methods: Serum ADMA, arginine and symmetric dimethylarginine (SDMA) levels were assessed by liquid chromatography in 61 AS and 26 osteoarthritis (OA) patients with no known cardiovascular disease. Results: Serum ADMA levels were significantly increased in AS compared to OA patients (0.95. ± 0.17. μM versus 0.70. ± 0.25. μM; p< 0.001). There were no differences in serum arginine and SDMA levels. Serum ADMA levels also positively correlated with age (R= 0.258; p= 0.043), body mass index (R= 0.368; p= 0.003), erythrocyte sedimentation rate (R= 0.329; p= 0.009) and ADMA levels negative correlated with chest expansion (R= -0.251; p= 0.04). No correlations were found between ADMA levels and disease duration, pain intensity, BASDAI, BASFI, BASMI, quality of life, CRP, HLA-B27 positivity, endothelial dysfunction or carotid atherosclerosis. Conclusion: ADMA may serve as a marker of systemic inflammation and may reflect functional immobility in AS. Further studies are needed to assess the possible role of ADMA in AS and AS-related vascular disease.

Original languageEnglish
Pages (from-to)184-187
Number of pages4
JournalJoint Bone Spine
Issue number2
Publication statusPublished - márc. 1 2011


ASJC Scopus subject areas

  • Rheumatology

Cite this